Quick Answer
aTYR PHARMA INC reported Diluted EPS of $0.80 per share (loss) for fiscal year 2025.
aTYR PHARMA INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.80 | +7.0% |
| 2024 | -$0.86 | +8.5% |
| 2023 | -$0.94 | +41.3% |
| 2022 | -$1.60 | +9.6% |
| 2021 | -$1.77 | +0.0% |
| 2020 | -$1.77 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.26 | -13.0% | -18.2% |
| June 30, 2025 | -$0.22 | +4.3% | -29.4% |
| March 31, 2025 | -$0.17 | +26.1% | +26.1% |
| September 30, 2024 | -$0.23 | -15.0% | +0.0% |
| June 30, 2024 | -$0.23 | -4.5% | +0.0% |
| March 31, 2024 | -$0.23 | +20.7% | -15.0% |
| September 30, 2023 | -$0.20 | +56.5% | +9.1% |
| June 30, 2023 | -$0.22 | +50.0% | +24.1% |
- aTYR PHARMA INC showed an increase of +7.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, aTYR PHARMA INC’s diluted eps has grown by 54.8% (from $1.77 per share (loss) to $0.80 per share (loss)).
- The most recent figure is from aTYR PHARMA INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: